Detalhe da pesquisa
1.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
N Engl J Med
; 383(6): 546-557, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757523
2.
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
Mult Scler
; 29(6): 753-756, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545928
3.
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Mult Scler
; 28(1): 111-120, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33969750
4.
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
N Engl J Med
; 379(9): 846-855, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157388
5.
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Mult Scler
; 26(7): 829-836, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968734
6.
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
BMC Neurol
; 20(1): 364, 2020 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33023488
7.
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
Mult Scler
; 28(2): 183-185, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35000468
8.
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
Mult Scler
; 23(4): 604-613, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27364322
9.
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
BMC Neurol
; 16: 102, 2016 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27416843
10.
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.
BMC Neurol
; 14: 49, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24624979
11.
Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
Ann Clin Transl Neurol
; 11(4): 842-855, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38366285
12.
SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.
Mult Scler Relat Disord
; 86: 105613, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38608516
13.
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
J Neurol
; 271(2): 711-722, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37995009
14.
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Neurol Ther
; 13(2): 283-322, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38206453
15.
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey.
Mult Scler J Exp Transl Clin
; 9(3): 20552173231198588, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37720692
16.
Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
Mult Scler Relat Disord
; 78: 104881, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556938
17.
Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review.
J Neurol Sci
; 453: 120816, 2023 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827008
18.
Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
J Neurol Sci
; 455: 122781, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979415
19.
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Mult Scler Relat Disord
; 75: 104766, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37245350
20.
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
CNS Drugs
; 36(12): 1285-1299, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36350491